Hepion Pharmaceuticals (HEPA)
(Delayed Data from NSDQ)
$0.76 USD
-0.06 (-7.20%)
Updated Aug 23, 2024 03:54 PM ET
After-Market: $0.74 -0.02 (-2.63%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Hepion Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 15 | 51 | 91 | 41 | 14 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 5 | 6 | 2 | 0 |
Total Current Assets | 17 | 57 | 97 | 43 | 14 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 2 | 2 | 2 |
Deposits & Other Assets | 0 | 4 | 4 | 3 | 3 |
Total Assets | 18 | 60 | 104 | 49 | 20 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 3 | 2 | 4 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 3 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 5 | 3 | 1 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 5 | 8 | 8 | 5 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 2 | 2 | 3 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 11 | 10 | 11 | 8 | 4 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 2 | 2 | 2 | 2 | 2 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 230 | 224 | 225 | 143 | 98 |
Retained Earnings | -225 | -176 | -134 | -104 | -83 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 7 | 50 | 93 | 41 | 16 |
Total Liabilities & Shareholder's Equity | 18 | 60 | 104 | 49 | 20 |
Total Common Equity | 6 | 48 | 91 | 39 | 14 |
Shares Outstanding | 4.30 | 3.80 | 3.80 | 0.40 | 0.10 |
Book Value Per Share | 1.30 | 12.67 | 24.03 | 97.03 | 144.70 |
Fiscal Year End for Hepion Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2 | 13 | 15 | 19 | 31 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 2 | 3 | 2 | 2 |
Total Current Assets | 5 | 15 | 17 | 21 | 33 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 3 | 4 |
Total Assets | 6 | 16 | 18 | 25 | 37 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 2 | 2 | 3 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 1 | 2 | 3 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 1 | 3 | 5 | 6 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 5 | 2 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2 | 8 | 11 | 9 | 10 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 2 | 2 | 2 | 2 | 2 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 233 | 233 | 230 | 228 | 228 |
Retained Earnings | -231 | -227 | -225 | -214 | -203 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 4 | 8 | 7 | 16 | 26 |
Total Liabilities & Shareholder's Equity | 6 | 16 | 18 | 25 | 37 |
Total Common Equity | 2 | 6 | 6 | 14 | 25 |
Shares Outstanding | 5.80 | 5.40 | 4.30 | 3.80 | 3.80 |
Book Value Per Share | 0.32 | 1.08 | 1.30 | 3.81 | 6.49 |